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In lymphocytes (LY), the well-documented antiproliferative eﬀects of IFN-α are associated with inhibition of protein synthesis,
decreased amino acid incorporation, and cell cycle arrest. However, the eﬀects of this cytokine on the metabolism of glucose and
glutamine in these cells have not been well investigated. Thus, mesenteric and spleen LY of male Wistar rats were cultured in the
presence or absence of IFN-α, and the changes on glucose and glutaminemetabolisms were investigated. The reduced proliferation
of mesenteric LY was accompanied by a reduction in glucose total consumption (35%), aerobic glucose metabolism (55%),
maximal activity of glucose-6-phosphate dehydrogenase (49%), citrate synthase activity (34%), total glutamine consumption
(30%), aerobic glutamine consumption (20.3%) and glutaminase activity (56%). In LY isolated from spleen, IFNα also reduced
the proliferation and impaired metabolism. These data demonstrate that in LY, the antiproliferative eﬀects of IFNα are associated
with a reduction in glucose and glutamine metabolisms.
1. Introduction
Interferon alpha (IFNα) was initially characterized as an
antiviral cytokine. Subsequently, several of its eﬀects were
demonstrated. Among them, the antiproliferative eﬀect is the
best characterized [1] and allows IFNα to be used in the
treatment of several tumors [2]. IFNα proteins are produced
both in response to infections as well as constitutively
and have a wide range of functions on diﬀerent cell types
including the modulation of lymphocyte (LY) activity [3, 4].
Thus, this cytokine is able to modulate the proliferation,
survival, and diﬀerentiation of LY [1]. The antiproliferative
eﬀect of IFNα on LY is related, for example, to the arrest of
the cell cycle [2] and inhibition of both protein synthesis and
amino acid incorporation [5].
LY activation is characterized by a state of high bio-
chemical activity [6] required to sustain proliferation and
the synthesis of several endogenous products in these cells
[7–10]. Because in LY glucose and glutamine consumptions
are strictly coupled to their cellular functions [11], the
uptake and consumption of both substrates is markedly
increased to cope up with the demands of activation. In this
scenario, not only precursor molecules used in DNA and
RNA synthesis are provided [11] but also the energy required
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by the biosynthetic processes [12]. Glucose and glutamine
metabolisms (and consequently LY functions) can be deter-
mined by the in vitro measurement of some key enzymes
from glycolysis, glutaminolysis, and the citric acid cycle [13].
In fact, we have previously determined the changes in LY
functionality induced by diﬀerent experimental conditions
using this methodology [14–16].
Considering the antiproliferative eﬀects of IFNα and the
importance of the glucose and glutaminemetabolisms for LY,
it is tempting to speculate that IFNα aﬀects the glucose and
glutamine metabolisms of these cells. Thus, the aim of the
present study was to evaluate the metabolism of glucose and
glutamine in LY frommesenteric lymph nodes and the spleen
of rats cultured in the presence of IFNα. Our hypothesis is
that the antiproliferative eﬀect of IFNα in lymphocytes can
be associated to a reduction of the glucose and glutamine
metabolism.
2. Material andMethods
2.1. Animals and Reagents. Male adult Wistar rats weighing
180 g (8 weeks old) from the Animal Breeding Unit, Institute
of Biomedical Sciences, University of Sa˜o Paulo, Sa˜o Paulo,
Brazil, were housed in a temperature-controlled room at
23◦C under a photoperiod regimen of a 12 : 12 hrs light : dark
cycle (lights on at 8:00 am) with water and commercial
food ad libitum. These animals were maintained in accor-
dance with the guidelines of the Brazilian Association for
Laboratory Animal Science, and all experimental procedures
were approved by the Ethical Committee on Animal Experi-
mentation of the Institute of Biomedical Sciences, University
of Sa˜o Paulo. The [U-14C]-glucose, [U-14C]-glutamine, and
[2-14C]-thymidine were purchased from Amersham (Little
Chalfont, Buckinghamsthire, UK). All other reagents includ-
ing IFN-α were purchased, unless specified, from Sigma (St
Louis, MO, USA) or Merck (Darmstadt, Germany).
2.2. LY from Spleen and Mesenteric Lymph Nodes. Organs
were extracted and cells extracted by pressing tissues against
a steel mesh as described by Ardawi and Newsholme [17].
The cell suspension was filtered (Whatman plc, Middlesex,
UK) and centrifuged at 150 g for 15min at 4◦C. The total
contamination with macrophages was lower than 1%.
2.3. Lymphocyte Proliferation. LY from spleen and mesen-
teric LY were cultivated in 96-well plates (1 × 105 cells per
well; Corning, One Riverfront Plaza, NY, USA) under sterile
conditions in GIBCO RPMI 1640 medium for 48 hrs at
37◦C in an artificially humidified atmosphere of 5% CO2
in a microprocessor incubator (LAB LINE, Boston MA).
Cells were also cultivated in the presence of concanavalin
A (ConA; 5 μg/mL), lipopolysaccharide (LPS; 10mg/mL) or
recombinant rat recombinant IFNα (1,000U/mL; added in
the beginning of culture periods). After 48 hrs in culture,
more than 98% of the lymphocytes were still viable, as
measured by trypan blue exclusion. The cells were labeled
with 7400 Bq 14C-thymidine (Amersham-GE Health-care,
Uppsala, Sweden) and diluted in sterile PBS yielding a final
concentration of 1 μg/mL. The cells were maintained under
these conditions for an additional 15 hrs and automatically
harvested using a multiple-cell harvester and filter paper
(Skatron Combi, Sulfolk, UK). The paper discs containing
the labeled cells were counted in 5mL Bray’s scintillation
cocktail in a Beckman-LS 5000TD liquid scintillator (Beck-
man Instruments, Fullerton, CA).
2.4. Incubation Procedure. LY from spleen and mesenteric LY
were incubated (1 × 106 cells per flask) at 37◦C in Krebs
Ringer medium with 2% fat-free bovine serum albumin
(BSA) in the presence of glucose (5mM) or glutamine
(2mM). After 1 hr, cells were disrupted with 200 μL 25%
(w/v) trichloroacetic acid, and the sample was neutralized
with 100 μL of 0.5M Tris containing 2.0M KOH for the
measurement of metabolites. Glucose consumption was
determined as previously described by Trinder [18]. Lactate
production was determined as previously described by Engle
and Jones [19]. Glutamine consumption was determined
using the method described by Windmueller and Spaeth
[20]. All spectrophotometric measurements were performed
in a Hitachi U-2001 spectrophotometer (Hitachi, Tokyo,
Japan) at 25◦C.
2.5. Glucose and Glutamine Oxidation. The 14CO2 produced
from 14C-glucose and 14C-glutamine oxidation was deter-
mined as described by Curi et al. [21]. LY were incubated
for 1 hr in the presence of one of the radiolabeled substrates
in a sealed Erlenmeyer flask (25mL) with one compartment
for cell incubation and a second one for CO2 collection, as
previously described by Kowalchuck et al. [22].
2.6. Enzymes. The activities of glucose-6-phosphate dehy-
drogenase (G6PDH), hexokinase (HK), and glutaminase
(GLUTase), enzymes that catalyse, respectively, the first
reaction of pentose phosphate and glycolitic and glu-
taminolytic pathways, were measured as previously described
by Bergmeyer et al. [23], Crabtree and Newsholme [24], and
Curthoys and Lowry [25], respectively. Citrate synthase (CS),
an important enzyme from the Krebs cycle, was measured
as described by Alp et al. [26]. The extraction media for
enzymes were: 25mM Tris-HCl buﬀer containing 1mM
EDTA and 30mM β-mercaptoethanol (for HK; pH 7.4),
50mM Tris-HCl containing 1mM EDTA (for GLUTase:
pH 8.6), 50mM Tris-HCl containing 1mMEDTA (for CS;
pH 7.4), and 50mM Tris-HCl containing 1mM EDTA (for
G6PDH; pH 8.0). For all enzyme assays, Triton X-100 was
added to the medium to a final concentration of 0.05%
(v/v). For HK activity, the following incubation medium was
used (pH 7.5); 75mM Tris-HCl containing 7.5mM MgCl2,
0.8mM EDTA, 1.5mM KCl, 4.0mM β-mercaptoethanol,
0.4mM creatine phosphate, 1.8U creatine kinase, 1.4U
glucose-6-posphate dehydrogenase, and 0.4mM NADP+.
The assay buﬀer for CS activity (pH 8.1) consisted of
100mM Tris-HCl, 0.2mM 5.5′-dithio-bis-2-nitrobenzoic
acid, 15mM acetyl-coenzyme A, and 0.5mM oxaloacetate.
The buﬀer for G6PDH (pH 7.6) consisted of 86mM Tris-
HCl containing 6.9mM MgCl2, 0.4mM NADP+, 1.2mM
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Table 1: Proliferation of splenocytes and mesenteric lymphocytes
cultured in the presence or absence of IFNα.
No add ConA LPS
C LFN 1003.6 ± 65.3 1954.5 ± 87.5 1753.1 ± 103.2
IFN LFN 875.4 ± 65.8† 1478.3 ± 76.3† 1165.9 ± 55.9†
C SPL 1231.2 ± 81.9 2309.6 ± 117.4 1987.3 ± 80.2
IFN SPL 845.1 ± 76.4  1543.9 ± 67.1  1456.3 ± 87.3 
The values are expressed as disintegrations per minute (DPM) and are
presented as mean ± SEM of 9 experiments. ConA: concanavalin A;
LPS: lipopolysaccharide; C LFN: mesenteric lymphocytes incubated in the
absence of IFNα; IFN LFN; mesenteric lymphocytes cultured with IFNα;
C SPL: splenocytes cultured in the absence of IFNα; SPL IFN splenocytes
cultured with IFNα. †P < .05 compared to C LY group.  P < .05 compared
with C SPL group.
glucose-6-phosphate, and 0.5% Triton X-100. The assay for
GLUTase (pH 8.6) consisted of 50mM potassium phosphate
buﬀer containing 0.2mM EDTA and 20mM glutamine. In
all cases, the final assay volume was 1.0mL. CS activity
was determined by absorbance at 412 nm and the other
enzymes at 340 nm. All spectrophotometric measurements
were performed in a Hitachi U-2001 spectrophotometer
(Hitachi, Tokyo, Japan) at 25◦C.
2.7. Protein Measurement. The protein content of the sam-
ples was measured by the method of Bradford [27]. BSA was
used as standard.
2.8. Statistical Analysis. Analysis was performed using
GraphPad-Prism. When diﬀerences among the groups were
detected by two-way factorial ANOVA, the Tukey test was
used. The level of significance of P < .05 was chosen for all
statistical comparisons. Data are presented as means ± SEM.
3. Results
3.1. Lymphocytes from Mesenteric Lymph Nodes. Lympho-
cytes obtained from mesenteric lymph nodes cultured in
the presence of IFNα (1000U/mL for 48 hrs) presented a
reduced proliferative index under all evaluated conditions
when compared to cells cultivated without this cytokine
(reduction by 13%, 24.4%, and 33.5%, when compared to
control, concanavalin A, and LPS experiments, respectively)
(Table 1). This reduction was accompanied by a reduction
of 49.2% of the maximal activity of glucose-6-phosphate
dehydrogenase (G6PDH) (Figure 1). Glucose utilization for
energetic processes was also reduced by IFNα as can be seen
by a 35.3% reduction in glucose consumption and a 55%
decrease in glucose decarboxylation (Figure 2). On the other
hand, maximal activity of hexokinase (HK) increased by 1.4-
fold in cells incubated with IFNα (Figure 1). The maximal
activities of citrate synthase (CS) and glutaminase (GLUTase
assay) were also reduced in lymphocytes incubated in the
presence of IFNα when compared to cells incubated without
the cytokine (34% and 56% reduction, resp.) (Figure 1). In
agreement with the result of the GLUTase assay, glutamine
consumption (−30.2%) and glutamine aerobic utilization
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Figure 1: Maximal activity of enzymes of mesenteric lymphocytes
cultured in the presence or absence of IFNα. The results are
expressed as nmol/min per mg of protein and represent the mean
± SEM of 9 experiments. HK: hexokinase; G6PDH: glucose-6-
phosphate dehydrogenase; CS: citrate synthase; GLUTase: phos-
phate dependent glutaminase. ∗P < .05 for comparison with the
control (C) group.
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Figure 2: Consumption and decarboxylation of glucose and
glutamine by mesenteric lymphocytes cultured in the presence or
absence of IFNα. The results are expressed as nmol/min per mg of
protein and represent the mean ± SEM of 9 experiments. ∗P < .05
for comparison with the control (C) group.
(−20.3%) were reduced by IFNα in comparison to cells
incubated without the cytokine (Figure 2).
3.2. Lymphocytes from Spleen. In lymphocytes obtained from
the spleen, IFNα promoted the same pattern of changes
in glucose and glutamine metabolism observed in lym-
phocytes from mesenteric lymph nodes. In comparison to
control cells cultivated without IFNα, lymphocytes from
the spleen presented a reduced proliferative index in all
conditions evaluated (reduction by 31.3%, 33.1%, and 27%,
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when compared with control, concanavalin A, and LPS
experiments, resp.) (Table 1). As observed for lymphocytes
obtained from mesenteric lymph nodes, most of the features
of glucose metabolism in LY from the spleen were reduced
by IFNα, as can be seen by the reduction of 43% in maximal
G6PDH activity (Figure 3) and a reduction of 22% in glucose
consumption (Figure 4). Again, the exception in glucose
metabolism was the 1.2-fold increased maximal HK activity
observed in the spleen LY when they were incubated in the
presence of IFNα in comparison to control cells (Figure 3).
Glutamine metabolism, on the other hand, was also reduced
in these LY due to IFNα activity. Glutamine consumption
decreased 21% and glutamine decarboxylation was reduced
23% in the presence of IFNα in comparison to control cells
(Figure 4). Glutamine decarboxylation was accompanied by
a reduction of 55.3% of the activity of important enzymes
from the citric acid cycle (Figure 3).
4. Discussion
The antiproliferative eﬀect of IFNα has been well described
in diﬀerent cell types [2] and has been related to the ability
of these cytokines to aﬀect several processes (e.g., protein
synthesis) required for LY activation [5]. Herein, we demon-
strate that glucose and glutamine metabolisms, particularly
important for LY activation [17], are also modulated by
IFNα.
As expected, our results confirm the antiproliferative
eﬀect of IFNα on LY from mesenteric lymph nodes and the
spleen. In fact, in a general sense, the cytokine promoted the
same pattern of changes in the metabolism of LY from these
diverse locations. Hence, the data of both LY populations will
be discussed together.
Confirming the strict relation between substrate use and
function in LY [11], the antiproliferative eﬀect of IFNα
was accompanied by a reduction in glucose and glutamine
metabolisms. Thus, our results added the reduction of
both substrates to the list of known factors related to the
antiproliferative eﬀect of IFNα.
In spite of being a nonessential amino acid, several
conditions such as infection and injuries can lead glutamine
to become “conditionally essential”. From this perspective,
investigations about the rate of utilization of glutamine by
immune cells have been performed aiming to open new ways
of therapeutic manipulation of the proliferative, phagocytic,
and secretory capacities of these cells [11]. As an example,
the lymphocyte mitogen concanavalin A increased both
glutaminase activity as well as glutamine utilization [28].
In this study, the antiproliferative eﬀect of IFNα on LY
was, however, accompanied by a reduction in glutaminase
maximal activity and glutamine consumption. Furthermore,
reductions of citrate synthase (CS) activity and of glutamine
decarboxylation demonstrate that aerobic pathways linked to
themetabolism of this amino acid were also aﬀected by IFNα.
Although both glucose and glutamine are utilized for
energy production by LY, the first seems to be quantitatively
more important [12]. In this study, LY cultured in the
presence of IFNα consumed less total glucose and presented
n
m
ol
/m
in
/m
g
pr
ot
ei
n
Control
INFα
∗∗
∗
∗
HK G6PDH CS GLUTase
0
20
40
60
80
100
120
140
Figure 3: Maximal activity of enzymes of lymphocytes from
spleen cultured in the presence or absence of IFNα. The results
are expressed as nmol/min per mg of protein and represent
the mean ± SEM of 9 experiments. HK: hexokinase; G6PDH:
glucose-6-phosphate dehydrogenase; CS: citrate synthase; GLUTase:
phosphate dependent glutaminase. ∗P < .05 for comparison with
the control (C) group.
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Figure 4: Consumption and decarboxylation of glucose and
glutamine by lymphocytes from spleen cultured in the presence or
absence of IFNα. The results are expressed as nmol/min per mg of
protein and represent the mean ± SEM of 9 experiments. ∗P < .05
for comparison with the control (C) group.
a reduced metabolism of this substrate by aerobic pathways
as demonstrated by the minor glucose decarboxylation and
activity of CS. Besides energy production, the reduction
of the maximal activity of G6PDh, the first enzyme of
the pentose-phosphate pathway, suggests that IFNα also
compromises proliferation by reducing the production of
metabolites and precursors needed for the biosynthesis of cell
components essential for proliferation [29]. Still considering
glucose metabolism, it is interesting to note that in spite
of the reduced glucose consumption, IFNα increased the
maximal activity of HK suggesting that the conversion of
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glucose to glucose-6-phosphate was not aﬀected by this
cytokine. Upon activation, LY increase their glucose uptake
via GLUT1 [30]. Thus, even if the increased HK activity
represents a greater glucose uptake in cultured LY the
greater enzyme activity was not enough to promote an
augment in glucose consumption because the subsequent
processes of glucose metabolism were downregulated by
IFNα.
In accordance withMacIver et al. [30], the understanding
of how normal LY function is regulated and fueled to allow
production of ATP and biosynthetic precursors essential
for growth and the eﬀector function of these cells is
very important due the severe downregulation of immune
functions which result from LY deficiencies.
Additionally, because many cancer cells consume glucose
in a manner similar to LY, that is, converting glucose to
lactate even in the presence of enough oxygen [31], it is
tempting to speculate that the results of the present study
could be relevant for the understanding of the role of IFNα
as an anticancer agent. Supporting this speculation, it has
been demonstrated that diﬀerent cancer cells can be resistant
to IFNα [32, 33]. This eﬀect could be associated with an
inadequate activation of the JAK-STAT pathway and its
eﬀectors STAT1 and STAT2. In this scenario, while adequate
levels of STAT1 are pivotal for the establishment of IFNα
eﬀects, low levels or overexpression of this transcription
factor seems to be advantageous for tumor cells [32].
Interestingly, a previously uncharacterized role of STAT1 in
regulating the expression of genes involved in glycolysis,
citrate cycle, and oxidative phosphorylation has been recently
demonstrated. On the other hand, we previously were able
to demonstrate that LY of tumor-bearing rats presented
reduced proliferation, glucose consumption, and maximal
activity of enzymes such as G6PDH and CS, while simultane-
ously, Walker 256 tumor cells of the same animals presented
an increased glucose metabolism [34].
As IFNα has antiapoptotic eﬀects on activated LY [35]
which are modulated by the metabolism of glucose and
glutamine [15], the metabolism of these substrates and
LY proliferation can be correlated with collagen-induced
arthritis [16], and the high glucose and lipid levels observed
in individuals with type 2 diabetes and obesity contribute
to LY activity promoting inflammation [30]. The results
presented here could be of relevance to other fields related
with immunology.
Thus, further investigations concerning the molecular
mechanisms underlying the eﬀects of IFNα (and other
cytokines) upon glucose and glutamine metabolisms as well
as proliferation of LY could lead to the development of
strategies to target cancer, autoimmune diseases and chronic
diseases.
5. Conclusions
In conclusion, our data suggest that the inhibition of
glucose and glutamine metabolism is an important part of
the mechanism of the antiproliferative eﬀect of IFNα in
lymphocytes from rats.
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